@article{2951152,
    title = "Efficacy and safety of single-agent ibrutinib in rituximab-refractory patients with Waldenström’s macroglobulinemia (WM): Initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATETM): 195",
    author = "Dimopoulos, M and Trotman, J and Tedeschi, A and Matous, J and Macdonald, D and Tam, C and Tournilhac, O and Ma, S and Oriol, A and Heffner, L and others",
    journal = "British Journal of Haematology",
    year = "2016",
    volume = "173",
    issn = "0007-1048, 1365-2141"
}